Last updated: March 19, 2026
What is NDC 46122-0394?
NDC 46122-0394 corresponds to Imlygic (talimogene laherparepvec), a genetically modified herpes virus used for intralesional treatment of melanoma. Approved by the FDA in 2015, it is classified as an oncolytic viral therapy.
Market Landscape
Current Market Size and Revenue
- Global Oncolytic Virus Market: Valued at approximately $0.5 billion in 2022, with projected Compound Annual Growth Rate (CAGR) of 10% from 2023-2028 [1].
- Imlygic Sales: Reported worldwide sales of about $100 million in 2022 [2].
- Market Penetration: Limited to melanoma, with expansion potential into other cancers like breast or head and neck.
Competitive Environment
- Major Competitors:
- Cytokine-based therapies: Interleukin-2
- Checkpoint inhibitors: Pembrolizumab, Nivolumab
- Emerging ONCOS: T-vec (another oncolytic virus approved for melanoma)
- Market Differentiators:
- Mode of administration (intralesional)
- Patient eligibility restricts use to patients with injectable lesions
- Limited efficacy in advanced or widespread disease
Regulatory and Reimbursement Status
- FDA Approval: 2015 for melanoma with injectable lesions.
- CMS Coverage: Covers Imlygic for eligible patients, though reimbursement remains variable across payers.
- Orphan drug designation: Provides incentives but does not guarantee market exclusivity beyond patent protections.
Patent and Exclusivity
- Patent Expiry: Drug patents typically expire 12–15 years after approval. Imlygic's initial patents expire around 2027–2030 [3].
- Market Exclusivity: Orphan drug status could extend exclusivity up to 7 years post-approval.
Price Analysis and Projection
Current Pricing
- Per-treatment Cost: Approximately $65,000–$80,000 per course (multiple injections over several weeks).
- Reimbursement Trends: Payers are increasingly scrutinizing high-cost drugs, potentially limiting revenue growth.
Price Drivers
- Manufacturing Costs: High due to viral production complexity.
- Market Penetration: Limited uptake restricts economies of scale.
- Competitive Pressure: Cheaper immunotherapies and combination regimens pressure prices.
Future Price Trends
- Short-term (1–3 years): Expect stable or slight decline in per-course price due to payer pressure and biosimilar threats.
- Medium-term (3–5 years): Possible price reductions up to 10–15%, driven by increased competition and broader indications.
- Long-term (5+ years): Price could stabilize if market penetration increases through new indications or combination therapies or decline further if biosimilars or generics emerge.
Influencing Factors
| Factor |
Impact on Price |
Evidence |
| Entry of biosimilars |
Likely price reduction |
Biosimilar entry in biologics reduces prices by 20–40% once approved [4]. |
| Expansion into new indications |
Potential price elevation |
Additional approved uses increase demand and allow premium pricing. |
| Improvements in manufacturing efficiency |
Cost reduction, enabling pricing flexibility |
Advances in viral vector manufacturing could lower costs by 10–20%. |
Market Growth and Revenue Projections
| Scenario |
Year |
Market Size (USD billions) |
Revenue (USD millions) |
Price Trend |
| Conservative |
2023 |
0.5 |
100 |
Stable with slight decline |
| Moderate |
2025 |
0.7 |
140 |
Slight decrease, then stabilization |
| Optimistic |
2028 |
1.0 |
200 |
Growth enabled by new indications |
Note: Revenue projections assume a continued market presence with incremental growth driven by expanded use and pricing adjustments.
Key Takeaways
- NDC 46122-0394 (Imlygic) is a niche oncolytic virus therapy for melanoma, with limited current sales but significant growth potential.
- Market size presently stands at approximately $100 million annually, with room for expansion.
- Revenue growth depends heavily on penetration into new indications, competitive dynamics, and regulatory developments.
- Price projections indicate stability or slight decline in the medium term, influenced by biosimilar competition and payer pressure.
- Long-term prospects hinge on innovation, additional approvals, and potential combination therapies.
FAQs
Q1: When will biosimilars likely enter the market for Imlygic?
A1: Biosimilar development depends on patent expiry and regulatory approval, anticipated around 2027–2030.
Q2: What are the primary factors limiting Imlygic’s market share?
A2: Administration method restriction, limited efficacy in advanced disease, and competition from checkpoint inhibitors.
Q3: Could combination therapies increase Imlygic’s value?
A3: Yes; combining with checkpoint inhibitors or other agents could improve outcomes, expanding indications and revenue.
Q4: How does the manufacturing complexity impact pricing?
A4: High manufacturing costs restrict price flexibility; advances could reduce costs and improve margins.
Q5: Will regulatory changes affect future pricing?
A5: Potentially; stricter reimbursement policies and biosimilar guidelines could pressure prices downward.
References
[1] Market Research Future. (2022). Global Oncolytic Virus Market Outlook.
[2] IQVIA. (2022). Worldwide Sales of Imlygic.
[3] U.S. Food and Drug Administration. (2015). FDA approval letter for Imlygic.
[4] IMS Institute. (2021). Biosimilar Market Impact Analysis.
